InterStim® Sacral Nerve Modulation Cycling Study

Completed · Not applicable

Conditions studied: Urinary Urge Incontinence

In brief

The study will assess the effects of different InterStim cycling settings on urinary urge incontinence.

Key facts

Study ID: NCT01957137
Run by: MedtronicNeuro
People needed: 30
Starts: 2013-09-01
Expected to finish: 2015-11-01
Last updated by the study team: 2017-12-12

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

Implanted with either Neurostimulator Model 3023 (InterStim) or Neurostimulator Model 3058 (InterStim II) for at least 3 months
Implanted with tined lead models 3889 or 3093
Tined lead is located at S3 as determined by sensory or motor responses or x-ray or fluoroscopy
Currently showing some efficacy with an InterStim device but has the potential to be optimized per the opinion of the Investigator
Primary diagnosis before InterStim implant is urinary urge incontinence.
Must be willing to maintain her current regimen (dosage and frequency) of any overactive bladder (OAB) medication (anticholinergic, antimuscarinic or Myrbetriq (Mirabegron)) or tricyclic antidepression medication over the study duration, if applicable.
Female subject 18 years of age or older
Willing and able to accurately complete voiding diaries and questionnaires, attend visits (within the visit windows +7 days), and comply with the study protocol that includes maintenance of InterStim programming settings over the course of the study
Have had no more than one (InterStim) reprogramming at or within 28 days at or prior to randomization
Able to consent to participate by signing the Informed Consent Form

You may not qualify if…

History of Multiple sclerosis
History of Reiter's syndrome
History of spinal cord injury or a cerebral vascular accident (CVA)
History of diabetes unless the diabetes is well-controlled through diet and/or medications
Active symptomatic urinary tract infection (UTI)
Stress incontinence as the primary diagnosis
Urgency frequency as a primary diagnosis
Pelvic pain of uncertain etiology that is not associated with a voiding dysfunction or where pelvic pain is the primary diagnosis
Interstitial cystitis as the primary diagnosis
Urinary retention as the primary diagnosis
Treatment of urinary symptoms with botulinum toxin in the past 12 months or any plan to have botulinum toxin treatment during the study
Bilateral lead placement
Have other implantable neurostimulator, pacemaker, or defibrillator
Have knowledge of planned diathermy, microwave exposure, high output ultrasonic exposure, RF energy exposure, or MRI scans not included within the scanning conditions provided within the MRI Guidelines for InterStim Therapy neurostimulation systems.
Have an anticipated system modification within the next 5 months
Women who are pregnant or planning to become pregnant (women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to randomization visit)
Subjects who frequently use the patient programmer to change device program settings ("frequently" is defined as at least once a day and does not include shutting off the device for safety purposes)
Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol.
Study site personnel will contact the Medtronic Study Manager (or designee) to determine if a potential subject who plans to enroll in an investigational device or drug trial, or is currently enrolled in an investigational device or drug trial is eligible for this study

Where it is running

Pinellas Urology, Inc. — St. Petersburg, Florida, United States
University of Iowa Healthcare — Iowa City, Iowa, United States
Metro Urology — Woodbury, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.